Literature DB >> 1611233

Peripheral site of action of levodropropizine in experimentally-induced cough: role of sensory neuropeptides.

A Lavezzo1, G Melillo, G Clavenna, C Omini.   

Abstract

The mechanism of action of levodropropizine has been investigated in different models of experimentally-induced cough in guinea-pigs. In particular it has been demonstrated that the antitussive drug has a peripheral site of action by injecting the drug intracerebroventricularly (i.c.v.). In these experiments levodropropizine (40 micrograms/50 microliters i.c.v.) did not prevent electrically-induced cough. On the other hand, codeine (5 micrograms/50 microliters i.c.v.) markedly prevented coughing. A difference in the potency ratio of levodropropizine and codeine has been demonstrated in capsaicin-induced cough; after oral administration, codeine was about two to three times more potent than levodropropizine. However, after aerosol administration the two compounds were equipotent. These data might suggest a peripheral site of action for levodropropizine which is related to sensory neuropeptides. Further support for the role of sensory neuropeptides in the mechanism of action of levodropropizine comes from the results obtained in capsaicin-desensitized animals. In this experimental model levodropropizine failed to prevent the vagally elicited cough in neuropeptide-depleted animals, whereas codeine did not differentiate between control and capsaicin-treated animals. In conclusion, our results support the suggestion that levodropropizine has a peripheral site of action. In addition, the interference with the sensory neuropeptide system may explain, at least in part, its activity in experimentally-induced cough.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611233     DOI: 10.1016/0952-0600(92)90033-d

Source DB:  PubMed          Journal:  Pulm Pharmacol        ISSN: 0952-0600


  6 in total

Review 1.  Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines.

Authors:  Donald C Bolser
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

2.  A case of immunoglobulin E mediated anaphylaxis to levodropropizine.

Authors:  Kyung Hee Park; Il Seon Yun; Soo-Young Choi; Jae-Hyun Lee; Chein-Soo Hong; Jung-Won Park
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

3.  Effects of levodropropizine on vagal afferent C-fibres in the cat.

Authors:  H Shams; L Daffonchio; P Scheid
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Virus-induced airway inflammation and hyperresponsiveness in the guinea-pig is inhibited by levodropropizine.

Authors:  G Folkerts; H J van der Linde; C Omini; F P Nijkamp
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-08       Impact factor: 3.000

5.  Levodropropizine for treating cough in adult and children: a meta-analysis of published studies.

Authors:  Alessandro Zanasi; Luigi Lanata; Giovanni Fontana; Federico Saibene; Peter Dicpinigaitis; Francesco De Blasio
Journal:  Multidiscip Respir Med       Date:  2015-05-31

6.  Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet.

Authors:  Soyoung Lee; Kyu-Yeol Nam; Beom-Jin Lee; Jang Hee Hong; Jaeseong Oh; SeungHwan Lee; Sang-Min Cho; Youn-Woong Choi; Joo-Youn Cho
Journal:  Drug Des Devel Ther       Date:  2018-05-23       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.